Design, synthesis and biological evaluation of (±)-kusunokinin derivatives as potent anticancer agents
Issued Date
2026-04-15
Resource Type
ISSN
02235234
eISSN
17683254
Scopus ID
2-s2.0-105030228185
Journal Title
European Journal of Medicinal Chemistry
Volume
308
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Medicinal Chemistry Vol.308 (2026)
Suggested Citation
Tangthana-umrung K., Taraporn S., DokDuang S., Benya-aphikul H., Tailangka A., Kornsakulkarn J., Tipmanee V., Thongpanchang C., Graidist P., Thongpanchang T. Design, synthesis and biological evaluation of (±)-kusunokinin derivatives as potent anticancer agents. European Journal of Medicinal Chemistry Vol.308 (2026). doi:10.1016/j.ejmech.2026.118677 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115261
Title
Design, synthesis and biological evaluation of (±)-kusunokinin derivatives as potent anticancer agents
Corresponding Author(s)
Other Contributor(s)
Abstract
Kusunokinin and its derivatives, which possess a dibenzylbutyrolactone core, have demonstrated notable anticancer activity, particularly against breast, ovarian, and cholangiocarcinoma cell lines. In this study, a series of (±)-kusunokinin derivatives were rationally designed based on previously reported bioactivity data to investigate structure–activity relationships (SAR) at the R, R′, and R″ positions of the aromatic rings. Structural modifications included the introduction of hydrogen bond donors, hydrogen bond acceptors, aromatic π-systems, and lipophilic groups. The influence of a methoxy substituent at the R″ position was also systematically evaluated. The derivatives were synthesized via a previously established route, utilizing (±)-intermediates 9 and 12 as the key building block. Hydroxyl protection and deprotection strategies were introduced, enabling selective functionalization of specific hydroxyl groups on the aromatic rings. Four compounds (13, 16, 18, and 33) exhibited cytotoxic activity against cholangiocarcinoma, triple-negative breast cancer, and ER-positive ductal carcinoma cell lines, while demonstrating lower cytotoxicity toward normal cells. Derivatives featuring an alkoxy or phenyl substituent at the R position and a hydroxyl group at R′ demonstrated enhanced cytotoxic activity. In contrast, the contribution of the methoxy group at R″ remains unclear and warrants further investigation. A discrepancy between the in silico screening results and experimental findings was also observed. These findings support the continued development of dibenzylbutyrolactone-based scaffolds as promising anticancer agents via targeting cancer-associated kinase.